Gilead's HepC Drug Sales May Be More Resilient Than Feared
April 02, 2014 at 11:10 AM EDT
Investors are fearful the launch of Gilead's (NASDAQ: GILD) HepC franchise has been too “rapid,” which will cause the drug's market ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.